Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,546 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,539 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05034991 | The Role of Endometrial Blood Flow in Endometrial Cancer | recruiting | — | 75 | Far Eastern Memorial HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05054296 | Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring | recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 29, 2023 |
| NCT05255471 | MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.(MITO 35B) | recruiting | Phase 3 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05715684 | Patient-Centered Surgical Prehabilitation(Prehab) | recruiting | N/A | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05753566 | Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer | recruiting | Phase 2 | 96 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05670938 | Follow-up After Surgery for Testicular Cancer(FUTURE-testis) | recruiting | — | 145 | Erasmus Medical CenterOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT05672485 | 99mTc-P137 SPECT/CT in Prostate Cancer | recruiting | N/A | 40 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT05733806 | Study on Gynecological Rare Cancers(MITO9B) | recruiting | — | 500 | National Cancer Institute, NaplesOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT05589207 | Predicting Model Based on Evidence-based Pathological Diagnose Criteria for RCC Tumor Thrombus With IVC Wall Invasion | recruiting | — | 232 | Peking University Third HospitalOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05722392 | Safety and Efficacy of Two-step Radical Prostatectomy | recruiting | — | 30 | Sun Yat-sen UniversityOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT03836196 | Optimizing Prostate Cancer Treatment in Men With Advanced Local Disease(OPTiMAL) | recruiting | N/A | 105 | British Columbia Cancer AgencyOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT04625556 | Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome | recruiting | — | 3,000 | Yonsei UniversityOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT02381990 | MRI/Ultrasound Fusion Guided Prostate Cryotherapy(FIPC) | recruiting | — | 5,000 | Urological Research Network, LLCOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05241236 | MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer(MRFLA) | recruiting | — | 5,000 | Urological Research Network, LLCOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05698576 | TRANBERG® Transperineal MR/US Fusion Laser--Induced Thermal Therapy for Men With Prostate Cancer(TPF-LITT) | recruiting | N/A | 20 | Urological Research Network, LLCOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05696002 | Advanced Pelvic Surgical Oncology Database - Prospective Observational Study | recruiting | — | 300 | Glasgow Royal InfirmaryOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT03621904 | PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer(PROMOTE) | recruiting | — | 150 | Radboud University Medical CenterOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT05607329 | Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial | recruiting | N/A | 400 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT05597852 | Using Rectal Hydrogel Spacer for Salvage SABR in Prostate Cancer(FIRST STAR) | recruiting | N/A | 10 | Sunnybrook Health Sciences CentreOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT04161664 | Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy(CRAVAT) | recruiting | Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05557604 | Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer(STUNNIN) | recruiting | Phase 2 | 146 | Regina Elena Cancer InstituteOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT05551208 | Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi | recruiting | Phase 2 | 42 | Chongqing University Cancer HospitalOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT05030805 | Transcriptional Map of Ovarian Cancer at the Single Cell Level(Ova-seq) | recruiting | — | 50 | University Hospital, Strasbourg, FranceOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT04403867 | The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Endometrial and Cervical Cancer. A Multicenter Study.(ITCMicroUtCa) | recruiting | — | 500 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05406999 | Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | recruiting | Phase 2 | 900 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT03789253 | Identify Genes/Pathways Responsible for Progression From Low Risk to Higher Risk Prostate Cancer | recruiting | — | 300 | National Taiwan University HospitalOTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT05500118 | Establishment of a Decision Aid Tool for Asymptomatic Small Leiomyoma and Analysis of Influencing Factors for Clinical Decision-making Using HIFU | recruiting | — | 120 | Shenzhen Maternity & Child Healthcare HospitalOTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT04914026 | MicroRNA as Markers in Testicular Cancer | recruiting | — | 350 | Haukeland University HospitalOTHER | 2 | Aug 8, 2022 | clinicaltrials |
| NCT05366478 | A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 15 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 2, 2022 | clinicaltrials |
| NCT04520074 | Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2) | recruiting | Phase 3 | 590 | Fudan UniversityOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT05415631 | Augmented Bladder Tumor Detection Using Real Time Based Artificial Intelligence(Bladder-PAD) | recruiting | — | 500 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT04595019 | Hypofractionated Expedited Radiotherapy for Men With localisEd proState Cancer(HERMES) | recruiting | N/A | 46 | Institute of Cancer Research, United KingdomOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT05395962 | Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer(Elechtra) | recruiting | Phase 2 | 92 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05367206 | Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial(N6C) | recruiting | Phase 3 | 280 | Sun Yat-sen UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05363657 | International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors(i-RECORd) | recruiting | — | 10,000 | Azienda Ospedaliero-Universitaria CareggiOTHER | 13 | May 6, 2022 | clinicaltrials |
| NCT05037825 | The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors(PARADIGM) | recruiting | — | 800 | VastBiomeINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT03753243 | Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer | recruiting | Phase 2 | 32 | Mark Garzotto, MDFED | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04894188 | Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer | recruiting | N/A | 38 | National Taiwan University HospitalOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT04478851 | EXCEL: Exercise for Cancer to Enhance Living Well(EXCEL) | recruiting | N/A | 1,500 | University of CalgaryOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03983226 | Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) | recruiting | Phase 2 | 167 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05214885 | Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma | recruiting | — | 300 | Qianfoshan HospitalOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT04845828 | Randomized Comparison Between Sentinel Lymph Node Biopsy and Lymph Node Dissection in Early Stage Endometrial Cancer(SELYE) | recruiting | N/A | 810 | Asan Medical CenterOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT05242861 | Retrospective Study of Brachytherapy(RetroBT) | recruiting | — | 300 | Zhejiang Cancer HospitalOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT04947059 | Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline)(GENSA) | recruiting | Phase 3 | 180 | University of ThessalyOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05206890 | A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer | recruiting | — | 490 | Tongji HospitalOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT04974346 | Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer(PAILACC) | recruiting | Phase 3 | 455 | Zhejiang Cancer HospitalOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT04712305 | Urine Omics Predicting IO Therapy Responses in mRCC Patients | recruiting | — | 400 | National Taiwan University HospitalOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT05072600 | Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer | recruiting | Phase 2 | 54 | Peking University First HospitalOTHER | 1 | Jan 10, 2022 | clinicaltrials |
| NCT05172310 | PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI | recruiting | Phase 1 | 410 | Karolinska University HospitalOTHER | 1 | Dec 29, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Mar 29, 2023source: clinicaltrials